Desloratadine is a second-generation antihistamine for treatment of allergic disorders. At therapeutic doses, desloratadine did not bind significantly to brain H1Rs and did not induce any significant sedation[3]. Of the second-generation antihistamines, desloratadine has the greatest binding affinity for the H1 receptor. Desloratadine and fexofenadine do not impair cognitive or psychomotor functioning and are comparable with placebo in terms of somnolence[4]. Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. Oral desloratadine 5 mg once daily for up to 4 weeks in patients with seasonal allergic rhinitis (SAR) significantly reduced nasal (including congestion) and non-nasal symptoms and improved health-related quality of life compared with placebo. Desloratadine 5 mg once daily for 6 weeks significantly improved pruritus and reduced the number of hives compared with placebo in patients with chronic idiopathic urticaria (CIU)[5].Desloratadine might have a negative effect on lactation in combination with a sympathomimetic agent such as pseudoephedrine[6]. Desloratadine treatment was also revealed to suppress colony-formation ability and induce cell cycle arrest at G1 phase in EJ cells. It promoted cell apoptosis via modulating the expression of Bcl-2, Bax, cleaved caspase 3, and cleaved caspase 9 in EJ and SW780 cells[7].
Brazil
... 展开 >> IMA - Instituto de Pesquisa Clínica e Medicina Avançada
Not yet recruiting
São Paulo, Brazil
Contact: Fabio M Castro, MD 55 11 38639156 daniela.fakih@imabrasil.com
Principal Investigator: Fabio M Castro, MD 收起 <<
Brazil
... 展开 >> Allergisa Pesquisa Dermato Cosmética Ltda.
Not yet recruiting
Campinas, São Paulo, Brazil
Contact: Mauro Crippa Jr. *55 19 3789-8615 收起 <<
搜索
